Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy

被引：0

作者：

Christoph, Daniel ^{[1
]}

Girard, N. ^{[2
]}

Smit, H. J. M. ^{[3
]}

Sibille, A. ^{[4
]}

Mcdonald, F. ^{[5
]}

Mornex, F. ^{[6
]}

Garassino, M. C. ^{[7
]}

Filippi, A. R. ^{[8
,9
]}

Peters, S. ^{[10
]}

Field, J. K. ^{[11
]}

Haakensen, V. Drageset ^{[12
]}

Bar, J. ^{[13
]}

Chouaid, C. ^{[14
]}

Bray, V. ^{[15
]}

Kao, S. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[18
]}

Garrido, P. ^{[19
]}

Fietkau, R. ^{[20
]}

机构：

[1] Evang Huyssens Stiftung Essen Huttrop, Evang Kliniken Essen Mitte, Dept Med Oncol Hematol, Essen, Germany

[2] Inst Curie & Montsouris, Inst Thorax, Paris, France

[3] Rijnstate Hosp, Dept Pulm Dis, Arnhem, Netherlands

[4] Ctr Hosp Univ Liege, Dept Pneumol & Allergol, Liege, Belgium

[5] Royal Marsden NHS Fdn Trust, Lung Unit, London, England

[6] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[7] Univ Chicago, Dept Hematol Oncol, Chicago, IL USA

[8] Fdn IRCCS Policlin San Matteo, Radiat Oncol Dept, Pavia, Italy

[9] Univ Pavia, Pavia, Italy

[10] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

[11] Univ Liverpool, Roy Castle Lung Canc Res Programme, Dept Mol & Clin Canc Med, Liverpool, England

[12] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[13] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[14] CHI Creteil, Serv Pneumol, Creteil, France

[15] Liverpool Hosp, Dept Med Oncol, Liverpool, NSW, Australia

[16] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[17] AstraZeneca, Oncol, Med Affairs, Gaithersburg, MD USA

[18] AstraZeneca, Oncol, Med Affairs, Paris, France

[19] Univ Alcala, Hosp Ramon y Cajal, Madrid, Spain

[20] Univ Klinikums Erlangen, Dept Radiat Oncol, Erlangen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

256

引用

页码：151 / 151

页数：1

共 50 条

[21] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Julian Taugner
Lukas Käsmann
Chukwuka Eze
Alexander Rühle
Amanda Tufman
Niels Reinmuth
Thomas Duell
Claus Belka
Farkhad Manapov
Investigational New Drugs, 2021, 39 : 1189 - 1196
[22] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Taugner, Julian
Kaesmann, Lukas
Eze, Chukwuka
Ruehle, Alexander
Tufman, Amanda
Reinmuth, Niels
Duell, Thomas
Belka, Claus
Manapov, Farkhad
INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1189 - 1196
[23] PACIFIC-6: A Phase II Study of Durvalumab after sequential Chemoradiotherapy in Patients with unresectable Stage III NSCLC
Wuerschmidt, F.
Garassino, M.
Faivre-Finn, C.
Mazieres, J.
Emeribe, U.
Franks, A.
Trunova, N.
Reck, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S88 - S88
[24] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
de Wit, M.
Spigel, D.
Faivre-Finn, C.
Gray, J.
Vicente, D.
Planchard, D.
Paz-Ares, L.
Vansteenkiste, J.
Garassino, M.
Hui, R.
Quantin, X.
Rimner, A.
Wu, Y. -L.
Ozguroglu, M.
Lee, K. H.
Kato, T.
Macpherson, E.
Newton, M.
Thiyagarajah, P.
Antonia, S.
Reck, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
[25] Real-world analysis of treatment patterns and efficacy of durvalumab maintenance after chemoradiotherapy in NSCLC patients
Taugner, J.
Kaesmann, L.
Eze, C.
Ruehle, A.
Tufman, A.
Reinmuth, N.
Duell, T. H-G-F.
Belka, C.
Manapov, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S742 - S742
[26] Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)
Faivre-Finn, C.
Jackson, D.
Abrams, K. R.
Hawkins, N. S.
Thiyagarajah, P.
Zhang, Y.
Hettle, R.
Dunlop, W.
Spigel, D. R.
ANNALS OF ONCOLOGY, 2021, 32 : S1408 - S1409
[27] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
Oh, H. -J.
Park, C. -K.
Kim, Y. -C.
Kim, Y. -H.
Ahn, S. -J.
Jeong, W. G.
Lee, J. Y.
Lee, J. C.
Choi, C. M.
Ji, W.
Song, S. Y.
Choi, J.
Lee, S. Y.
Kim, H.
Lee, S. Y.
Park, J.
Yoon, S. H.
Joo, J. H.
Oh, I. -J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
[28] Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
Gibson, A.
Dean, M.
Elegbede, A.
Pabani, A.
Bebb, G.
Cheung, W.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S282 - S283
[29] Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
Huang, Y.
Zhao, J.
Soon, Y. Y.
Wong, A.
Ang, Y.
Asokumaran, Y.
Low, J. L.
Lee, M.
Choo, J.
Chan, G.
Kee, A.
Tay, S. H.
Goh, B. C.
Soo, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1044 - S1044
[30] Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab
Nindra, Udit
Shahnam, Adel
Stevens, Samuel
Pal, Abhijit
Nagrial, Adnan
Lee, Jenny
Yip, Po Yee
Adam, Tamiem
Boyer, Michael
Kao, Steven
Bray, Victoria
THORACIC CANCER, 2022, 13 (21) : 3058 - 3062

← 1 2 3 4 5 →